July 3 (Bloomberg) -- Drugmakers operating in Europe must disclose payments made to doctors starting in 2016 in an effort to boost transparency and make patients aware of possible conflicts of interest.
The new ethical code requires all members of the European Federation of Pharmaceutical Industries and Associations to disclose payments made in 2015 by 2016, the trade group said in a statement yesterday.
Each company must reveal names of health-care professionals and associations that have received payments, the amounts, and the types of relationships on their websites or on a common website, EFPIA said. The rule follows a similar U.S. provision in President Barack Obama’s health law.
“This is an important step for our industry, as we demonstrate our commitment to transparency and secure the trust of the patients our industry serves,” Richard Bergstroem, director general of EFPIA, said in the statement.
The Association of the British Pharmaceutical Industry started publishing aggregate totals in May of payments made last year to health-care professionals.
To contact the reporter on this story: Makiko Kitamura in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com